SAS2094AH and SAS2094BH

Small molecule

BBrigham and Women's Hospital

SAS2094AH and SAS2094BH is one of 4 small molecule programs targeting Snoring. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SnoringActive, not recruiting

SnoringPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Snoring

#DrugCompanyPhaseTrials

XEOMIN

MMerz Pharmaceuticals GmbH

Phase 2

1 2

Pulmicort

SSalix

Phase 1

1 3

Bloxiverz

FFresenius Kabi Oncology Ltd.

Phase 1

1 4

SAS2094AH and SAS2094BH

BBrigham and Women's Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Snoring1 trial

Pharmacological Intervention for Symptomatic Snoring

Completed·—·Phase 1/2·NCT03720353·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SAS2094AH and SAS2094BH. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAS2094AH and SAS2094BH compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAS2094AH and SAS2094BH. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Brigham and Women's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: BBrigham and Women's Hospital

SAS2094AH and SAS2094BH

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Snoring1 trial

References

Drug Info

Quick Facts

Related News